| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 190,553 | 158,702 | ||
| Investments in marketable securities | 73,290 | 72,296 | ||
| Accounts receivable | 113,838 | 105,849 | ||
| Inventories | 177,928 | 154,875 | ||
| Prepaid expenses and other current assets | 38,457 | 46,285 | ||
| Total current assets | 594,066 | 538,007 | ||
| Operating lease right-of-use assets, net | 21,549 | 21,988 | ||
| Property and equipment, less accumulated depreciation of 31,271 and 28,775 at september 30, 2025 and december 31, 2024, respectively | 27,759 | 28,570 | ||
| Intangible assets, less accumulated amortization of 8,257 and 5,802 at september 30, 2025 and december 31, 2024, respectively | 14,743 | 15,570 | ||
| Goodwill | 197,797 | 197,797 | ||
| Other non-current assets | 12,897 | 13,371 | ||
| Total assets | 868,811 | 815,303 | ||
| Accounts payable | 19,103 | 13,893 | ||
| Accrued expenses and other current liabilities | 171,165 | 145,144 | ||
| Operating lease liabilities | 8,662 | 8,610 | ||
| Total current liabilities | 198,930 | 167,647 | ||
| Long-term debt | 391,985 | 391,322 | ||
| Operating lease liabilities | 42,174 | 43,383 | ||
| Other non-current liabilities | 5,298 | 8,647 | ||
| Total liabilities | 638,387 | 610,999 | ||
| Common stock, 0.01 par value, 500,000,000 shares authorized, 308,499,614 and 299,041,653 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 3,017 | 3,016 | ||
| Common stock in treasury, at cost 7,390 shares as of september 30, 2025 | 71 | 71 | ||
| Additional paid-in capital | 2,973,625 | 2,956,839 | ||
| Foreign currency translation adjustment | 22,886 | 30,935 | ||
| Unrealized loss on available-for-sale securities | -53 | -129 | ||
| Warrants | 0 | 0 | ||
| Accumulated deficit | -2,768,980 | -2,786,286 | ||
| Total stockholders equity | 230,424 | 204,304 | ||
| Total liabilities and stockholders equity | 868,811 | 815,303 | ||
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD)